GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

January 19, 2024

https://www.globenewswire.com/news-release/2024/01/18/2811983/0/en/GH-Research-Announces-Grant-of-European-Patent-Covering-all-Mebufotenin-5-MeO-DMT-and-Mebufotenin-Salt-Products-For-Use-in-the-Treatment-of-Major-Depressive-Disorder-and-Treatment-.html

DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it recently received a communication from the European Patent Office (EPO) that it has been granted a patent with claims directed to mebufotenin (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in treating patients diagnosed with major depressive disorder (MDD) and treatment-resistant forms of MDD, such as treatment-resistant depression (TRD).

Read more at globenewswire.com

Related news for (GHRS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.